Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease  by Baboolal, Keshwar et al.
Kidney International, Vol. 52 (1997), PP. 607—613
GENETIC DISORDERS - DEVELOPMENT
Association of the angiotensin I converting enzyme gene deletion
polymorphism with early onset of ESRF in PKD1 adult polycystic
kidney disease
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Association of the angiotensin I converting enzyme gene deletion
polymorphism with early onset of ESRF in P.KD1 adult polycystic kidney
disease. To determine the effect of the ACE gene insertion/deletion (I/D)
polymorphism, angiotensinogen gene M235T polymorphism and the
angiotensin I receptor gene Al 166C polymorphism on the age of onset of
end-stage renal failure (ESRF) in PKDI adult autosomal-dominant poly-
cystic kidney disease (ADPKD), 189 individuals from 46 families with
PKDI were genotyped for each polymorphism. Of the 189 patients 52
(28%) reached ESRF at an average age of 48 1 year. In patients
genotyped for the ACE gene insertion/deletion polymorphism the fre-
quencies of the DD, ID and II genotypes were similar to those expected
from Hardy Weinberg equilibrium. In patients with ESRF there was an
excess of patients homozygous for the deletion allele (DD: 48% = 9.97(ldf) P = 0.002). Cumulative renal survival was significantly reduced
among those with DD genotype compared to ID and II genotypes. The
estimated mean renal survival (95% confidence intervals) were: DD, 52
years [48, 57]; II, 59 years [54, 63]; ID, 64 years [56, 72]; = 6.13 (ldf)
P = 0.013, DD versus ID/Il. The mean age of renal failure was significantly
younger in the DD genotype compared to ID and II genotypes (DD, ID,
and II: 44 2, 49 2 and 54 3 years, respectively; P < 0.05 DD vs. ID,
P < 0.05 DD vs. II). Ten of the eleven patients who reached ESRF before
the age of 40 were homozygous for the deletion allele. The relative risk for
ESRF below the age 40 for DD genotype was 17. For all ages there was an
overall increased risk of 1.4 for ESRF with the DD genotype. There was
no interaction between age of onset of ESRF and either the angiotensino-
gen M235T allele or angiotensin 1 receptor A1166C polymorphism. This
study strongly suggests that PKD I patients homozygous for the deletion
allele of the ACE gene are at increased risk of developing ESRF at a early
age.
Autosomal-dominant polycystic kidney disease (ADPKD) is a
common genetic disorder that accounts for 8 to 10% of end-stage
renal failure (ESRF) world wide [1]. Renal disease is character-
ized by the development of hypertension and a variable rate of
progression to ESRF. In general, patients show a prolonged
period of normal renal function, but once renal failure starts, it
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progresses to ESRF within 10 years [2, 31. In some patients ESRF
occurs in adolescence while in others ESRF does not occur at all
[2—5]. Among those who develop ESRF the mean age at onset is
approximately 50 years [3]. The rate of progression to ESRF is
variable and depends on complex interactions between the geno-
types responsible for ADPKD, other modifying genes and envi-
ronmental factors.
Some of the clinical variability is accounted for by differences in
the genotypes responsible for the clinical syndrome of ADPKD.
At least three different genes code for the development of
ADPKD with loci mapped to chromosome 16: polycystic kidney
disease 1 (PK.D1) [6, 7], to chromosome 4 (PKD2) [8] and
recently, a small number of families with ADPKD that are not
linked to the PKD1 and PKD2 loci have been identified [9, 10].
Phenotype expression differs between PKD1 and PKD2 genotypes.
PKDJ is a more severe disease with a higher incidence of
hypertension and a higher risk of progression to ESRF [11—13].
Several studies have demonstrated increased activity of the
renin-angiotensin system in ADPKD [14—16]. The renin-angio-
tensin system is considered to play an important role in the
control of renal function, genesis of hypertension and the subse-
quent development of ESRF in ADPKD [14, 15, 17—19].
Recently, human genetic studies have revealed the presence of
polymorphisms in genes encoding key components of the renin-
angiotensin system and that some of these genetic variation
accounts for a proportion of the variance in activity of the
renin-angiotensin system [20]. More recently these genetic poly-
morphisms have also been associated with susceptibility to the
development and rate of progression of renal diseases [21—30].
One such genetic variant is the insertion/deletion polymor-
phism of angiotensin converting enzyme (ACE) gene. Studies by
Rigat and Costerousse have demonstrated increased circulating
and tissue levels of ACE in patients homozygous for the deletion
allele [31, 32]. Within the kidney ACE is the rate limiting step of
the renin-angiotensin enzyme cascade [33]. It has been hypothe-
sized that increased levels of ACE result in increased conversion
of angiotensin I to the biologically active ligand, angiotensin II.
Several studies have also suggested that the ACE gene deletion
allele confers susceptibility to the development of renal injury and
identifies groups of patients with established renal injury who
progress more rapidly to ESRF [21—27].
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A point mutation of a nucleic acid at codon 235 in the
angiotensinogen IATG) gene leads to an amino acid substitution
of threonine (T) for methionine (M). This ATG M235T polymor-
phism has been associated with increased plasma concentrations
of angiotensinogen. Clinical studies have demonstrated an asso-
ciation between theATG M235T polymorphism and the develop-
ment of hypertension and diabetic nephropathy [20, 30].
Finally, a nucleic acid substitution of A with C at position 1166
in the angiotensin I receptor (A Ti) gene (A1166C) has been
identified. The function of the angiotensin 1 receptor (AT]) gene
(A1166C) has not yet been established, but has been associated
with the development of hypertension and coronary heart disease
[28, 29]. Studies in cardiovascular disease, but not in renal
diseases, have also demonstrated a synergistic effect of the AT1
gene Al 166C polymorphism and ACE gene deletion polymor-
phism on risk of myocardial infarction [28].
Together these studies demonstrate that polymorphic variants
of the renin-angiotensin system influence the level of the activity
of the renin-angiotensin system, and are associated with increased
susceptibility to and progression of renal diseases.
In view of the important role that the renin-angiotensin system
plays in the development of ESRF in ADPKD, we hypothesized
that molecular variants of the renin-angiotensin system account
for some of variability on age at onset of ESRF in PKDJ ADPKD.
We assessed the effects of the ACE insertion/deletion, ATG
M235T andATi Al 166C polymorphisms on age of onset of ESRF
among 189 individuals from 46 families with PKD1.
METHODS
Identification of families and affected members
Index cases were ascertained in South Wales, UK and Victoria,
Australia. Pedigrees were constructed and individuals with
ADPKD were identified. One hundred and eighty-nine PKDZ
affected individuals from 46 families were identified. A clinical
diagnosis of ADPKD was defined by the presence of at least five
renal cysts distributed between both kidneys. The diagnosis was
established by ultrasonography, computed tomography, excretory
urography, by autopsy report or by report of death from chronic
renal failure, with a clinical diagnosis of autosomal-dominant
polycystic kidney disease. Each family was demonstrated to have
PKDJ by linkage studies [11]. All individuals had given consent for
inclusion in family linkage studies in both centers. The majority of
PKDI families were of European origin. Among the 18 PKDJ
families from Australia, ancestors with ADPKD were known to
have migrated from the UK [8], Ireland [4] and Italy [1]. Five
Australian families did not know their original European country
of origin.
Clinical manifestations
The age at onset of end-stage renal disease was taken to be the
age at which long-term replacement therapy for renal function
became necessary, or in people who died of renal failure, the age
at death. Blood pressure measurements were made with the
subject seated; the fifth Korotokoff sound was used to determine
diastolic pressure. Subjects were classified as hypertensive if the
systolic or diastolic blood pressure exceeded the 95th percentile
for their age and sex [34] or if they were taking antihypertensive
medication.
Molecular studies
DNA was extracted from peripheral blood lymphocytes. DNA
was extracted according to the manufacturer's recommendations
using the Nucleon II DNA extraction kit (Scotlab, Strathclyde,
Scotland, UK). Genomic DNA was suspended in 10 mtvi Tris-HC1,
1 mM EDTA, pH 8.0, and concentrations were measured by
spectrophotometry.
The ACE insertion/deletion polymorphism in intron 16 of the
ACE gene was amplified with the flanking primers: 5'-CTG GAC
ACC ACT CCC ATC CiT TCT-3'and 5'-GAT GTG GCC ATC
ACA TIC GTC AGA-3'. The PCR reaction was carried out in a
final reaction volume of 12.5 pA and contained 12.5 M of each
primer, 200 tLM ofeach dNTP, 2.0 mrvi MgCl2, 50 mMKC1. 10 mi
Tris-HCI pH 8.3, 1 unit Taq polymerase and 48 ng of genomic
DNA. A two step, 40 cycle protocol was used consisting of a
combined elongation/annealing stage of 72°C for one minute and
a denaturing stage at 94°C for one minute. The final elongation
step was at 72°C for 10 minutes. Amplified products were
separated and sized on a 1% agarose gel. The insertion (I) and
deletion (D) products gave band sizes of 490 bp and 190 bp,
respectively.
Heterozygotes ID individuals can be mistyped as DD homozy-
gotes due to preferential amplification of the smaller D allele [35].
To check for these typing errors and further validate the data, an
insertion specific PCR was performed on all individuals typed as
DD homozygotes. Reactions were carried out in a final volume of
12.5 pA containing 12.5 pm of each primer (5'- TGG GAC CAC
AGC GCC CGC CAC TAC-3' and 5'- TCG CCA GCC CTC
CCA TGC CCA TAA-3'), 200 LM of each dNTP, 2.0 mM MgC12,
50 mMKCI, 10 mM Tris-HC1 pH 8.3, 1 unit Taq polymerase and 48
ng of genomic DNA. Following denaturation at 94°C for five
minutes, 35 cycles of annealing at 60°C, elongation at 72°C and
denaturation at 94°C for 30 seconds, was performed before a final
elongation step of 72°C for 10 minutes. Amplified products were
resolved on a 1% agarose gel. In the presence of the insertion a
335 bp fragment was amplified. True DD homozygotes yielded no
product.
To determine the AT] A1166C polymorphism of the angioten-
sin II receptor gene, a simple PCR formatted RFLP assay was
used. Flanking primers (5'-GCA CCA TGT 'IVIT GAG G1T-3'
and 5'-CGA CTA CTG CTT AGC ATA-3') amplified a 546 bp
region incorporating position 1166 where the presence of the C
nucleotide introduces a DdeI cut site. Reactions were carried out
in a final volume of 12.5 pI containing 12.5 M of each primer, 200
LM of each dNTP, 2.0 mrvt MgCl2, 50 mMKCI, 10 mivi Tris-HCI ph
8.3, 1 unit Taq polymerase and 48 ng of genomic DNA. Following
denaturation at 94°C for five minutes, 35 cycles of annealing at
52°C, elongation at 72°C and denaturation at 94°C for 30 seconds,
was performed before a final elongation step of 72°C for 10
minutes. To the amplified products were then added 10 units of
DdeI, 2 il of buffer (Gibco BRL) and the reaction volume
adjusted to 20 pA with ddH2O. Samples were incubated at 37°C for
two hours. The digestion products were resolved on a 1% agarose
gel. Allele 1 (546 bp) corresponded to an A at position 1166
(absence of a DdeI site) and allele 2 (435 bp) to a C (presence of
a DdeI Site).
The M235T polymorphism of the angiotensinogen gene was
also detected by a PCR-formatted RFLP assay. The T-C transi-
tion at position 704 in exon 2 produced a half site for Tth 111 I,
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which could be detected by incorporation of two mismatches in
the downstream primer. The PCR reaction was carried out in a
final reaction volume of 12.5 p of each primer (5'-CAG GGT
GCT GTC CAC ACT GGA CCC C-3' and 5'-CCG TTT GTG
CAG GGC CTG GCT CTC T-3', 200 LMof each dNTP, 2.0 mM
MgCI2, 50 mMKCI, 10 mrvi Tris-HC1, pH 8.3, 1 unit Taq polymer-
ase and 48 ng of genomic DNA. A two step, 40 cycle protocol was
used consisting of a combined elongation/annealing stage of 72°C
for one minute and a denaturing stage at 94°C for one minute.
The final elongation step was at 72°C for 10 minutes. To the
amplified products were then added 10 units of Tth 1111, 2 jil of
buffer (Gibco BRL) and the reaction volume adjusted to 20 j.tI
with ddH2O. Samples were incubated at 37°C for two hours. The
digestion products were resolved on a 3.5% agarose gel. Allele 1
(165 bp) corresponded to a T at position 704 (absence of a Tth 111
I site) and allele 2 (141 bp) to a C (presence of a Tth 1111 site).
Genotypes for the 3 polymorphisms (A CE,A TI and AGT) were
assessed by two independent raters blind to the patients' details.
Statistics
For the analysis of the time course to the initiation of renal
replacement therapy, a cumulative survival analysis using Cox
regression was performed. The potential influence on the age of
onset of renal failure of each gene polymorphism as well as gender
and country of origin was assessed. When comparing the hyper-
tension rate associated with each polymorphism, the log rank test
was used. The t-test for independent populations was used to
compare continuous variables. Two tailed chi squared tests were
used to compare qualitative variables. P < 0.05 was regarded as
statistically significant.
RESULTS
General characteristics of PKD1 ADPKD patients
Baseline characteristics of the 189 patients are illustrated in
Table 1. The average age of the patient population was 38 1
years. Of the 189 patients 52 (28%) reached ESRF at a mean age
of 48 years (range 26—72). Figure 1 illustrates the age and sex
distribution of ESRF in patients with PKDI ADPKD. At the time
of study, 11% (11 of 96) of the patients aged less than 40, 48% (21
of 43) of the patients aged 41 to 49 and 40% (20 of 50) aged older
than 50 had reached ESRF. Although there was a tendency for an
increased risk of ESRF in females, this was not statistically
significant [ = 2.36, (ldf) P = NS]. The mean age of onset of
ESRF in males and females was identical. The age and sex dis-
tribution of ESRF are similar to those previously reported [2, 3].
Influence of ACE gene polymorphism on age of onset of ESRF
Among the 189 patients the frequencies of the ACE genotypes
DD, ID and II were 34%, 44% and 22%, respectively (Table 1).
The genotype distribution was similar to that expected from the
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Hardy Weinberg equilibrium [x2 = 2.27, (ldf) P = 0.131. There
was no difference between the groups for age. The prevalence of
hypertension was similar to previously published reports and was
similar between the three genotypes [log rank test 0.33, (2df) P =
0.848] [3, 36, 37].
In contrast, in those patients with renal failure, the genotype
frequencies were significantly different from those expected, with
an excess of patients homozygous for the deletion allele [DD, ID,
II: 48%, 27%, 25%, respectively; x2 = 9.97, (ldf) P = 0.002].
Cumulative renal survival (Fig. 2) was also lower in patients
homozygous for the deletion allele compared to heterozygotes
(ID) and homozygotes for the insertion allele. The estimated
mean renal survival (95% confidence intervals) were: DD, 52
years [48, 57]; 11, 59 years [54, 63]; ID, 64 years [56, 72]. These
differences in renal survival were statistically significant [, =
6.13, (ldf) P = 0.013; DD versus Il/ID]. There was no difference
in renal survival between the II and ID polymorphisms [ = 0.62,
(ldf) P = NS].
The majority of patients who reached ESRF before the age of
50 were homozygous for the deletion allele. Ten patients out of
eleven who reached ESRF before the age of 40 were homozygous
for the deletion allele. Among those patients who reached ESRF
between ages of 40 to 49, 43% (9 of 21) were DD genotype. There
was a significant over-representation of patients homozygous for
the deletion allele who reached ESRF before the age of 50 [DD
vs. ID/Il, = 4.87, (ldf) P = 0.027]. The distribution of
genotypes became more equal with increasing age of onset of
ESRF. The relative risk for ESRF below the age 40 for the DD
genotype was 17, 2.2 by the age 50, and 1.3 by the age 60. For all
ages there was an overall increased risk of 1,4 [1.2, 1.8] for ESRF
with the DD genotype.
Cumulative renal survival was not affected by censoring of
patients due to death prior to the onset of ESRF. Of the 189
patients genotyped, five patients died before the development of
ESRF, two with DD polymorphism, two with ID and one with II
polymorphism. Of these five patients, two died before the age of
50.
A further analysis was performed to examine whether there was
a synergistic effect of sex and ACE genotype on age of onset of
renal failure in PKD1 patients. We found no interaction between
Table 1. Baseline characteristics of the 189 patients with PKD/
ADPKD
DD ID II Total
N 64 83 42 189
Age 37±2 38±2 38±2 38±1
M:F 29:35 38:45 18:24 85:104
Hypertension 62% 61% 53°/ 59%
12
26—30 31—36 36—40 41—45 46-50 51—55 56—60 61-65 66—70 71—76
Age at ESRF
Fig. 1. Age and sex distribution of patients with PKD1 ADPKD who
reached ESRF. Symbols are: (U) female; (E) male.
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sex and the ACE genotype on age of onset of ESRF [x2 = 5.06,
(2df) P = NS]. We also found no interaction between the ACE
genotype and country of origin [x2 = 1.99, (2df) P = NS]. The
association of the deletion allele with early age of onset of ESRF
was maintained in both countries.
There was no interaction between age of onset of renal failure
and either the angiotensinogen M235T polymorphism [ = 2.77,
(2df) P = NS] or angiotensin 1 receptor (A1166C) polymorphism
[x2 = 1.14, (2df) P = NS] by Cox regression analysis. There was
no synergistic effect between the ACE gene DD polymorphism
and ATG M235T polymorphism or angiotensin I receptor
Al 166C polymorphism.
To examine a possible mechanism by which the ACE gene
deletion polymorphism resulted in the early development of
ESRF, we examined whether the prevalence of hypertension in
patients aged less than 40 was higher in the DD genotype. These
data revealed that the prevalence of hypertension among the
patients aged less than 40 was not higher in the DD polymorphism
compared to ID and II. Fifty percent (13 of 26) of patient with DD
polymorphism aged less than 40 developed hypertension com-
pared to 33% (14 of 42) with ID and 35% (6 of 17) with II
polymorphisms [log rank test 3.25, (2df) P = 0.1971. Patients with
ESRF were censored from this analysis. Even when patients with
ESRF were included in the analysis the prevalence of hyperten-
sion in the age group less than 40 was not higher in DD patients
[log rank test 3.25, (2df) P 0.154].
DISCUSSION
The natural history of ADPKD has been well defined [3, 5].
Both genetic and environmental factors are considered to play an
important role in determining the variable age of onset of ESRF.
Several studies have shown that PKD1 locus is associated with an
earlier onset of ESRF compared to non-PKDJ genotypes [11—13].
It has also been hypothesized that phenotypic variation in AD-
PKD may result from mutations within the PKDJ gene. However,
as yet, evidence to support this hypothesis is lacking [38].
In our study, we examined whether the PKDI gene interacts
with other modifying genes to determine phenotype. Results from
our study have shown that coexpression of the ACE DD genotype
and the PKDJ gene accounts for some of the variability in age at
onset of ESRF in ADPKD. Patients with the DD polymorphism
reach ESRF at a younger age than ID and II polymorphisms. For
all ages there was an increased risk of 1.4 (1.2, 1.8) for ESRF with
the DD genotype.
In accord with previous studies, approximately 11% of the
ADPKD population had reached ESRF before the age of 40, and
23% of the ADPKD population had reached ESRF before the age
of 50 [2, 3]. The majority of patients who reached ESRF before
the age of 40 were homozygous for the deletion polymorphism.
There was a more than 17-fold increased risk of ESRF in those
patients homozygous for the deletion polymorphism below the
age of 40 compared to II and ID genotypes. For those aged
between 40 and 50 there was more than twofold increased risk for
ESRF for patients with the DD genotype. However, for those
aged 50 and above there was a progressive reduction in the effect
of DD genotype on the development of ESRF. This suggests that
DD genotype identifies patients who may reach ESRF at a young
age but does not explain the development of ESRF in all age
groups. In agreement with other studies, we found no association
between the M235T polymorphism of the ATG or the ATI gene
A1166C polymorphism with age at onset of ESRF [23, 26].
Further, there was no synergistic effect detected between the
polymorphisms of the angiotensinogen, angiotensin I receptor
and AE gene and age at onset of ESRF.
Our study is consistent with several previous studies that report
an association between the deletion polymorphism of the ACE
gene and accelerated loss of renal function. In these studies, the
deletion polymorphism identified subgroups of patients with IgA
nephropathy, diabetic nephropathy and chronic renal injury [23—
25, 27, 391 who had a more rapid decline in renal function and
earlier onset of ESRF.
While our findings and previous reports are consistent with
experimental evidence indicating a role for angiotensin II in the
progression of renal injury, considerable controversy has emerged
over the influence of the ACE gene polymorphism on the
development of renal injury. It must be noted that not all studies
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Fig. 2. Cumulative renal survival for each ACE
gene polymorphism. Cumulative renal survival
was lower in patients homozygous for the
deletion polymorphism prior to DD vs. ID/Il
[DD vs. ID/Il, x2 = 6.13, (ldf) P = 0.013].
80 There was no difference in renal survival
between the II and ID polymorphisms ft2
0.62, (ldf) P = NSJ.
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have been able to demonstrate that the deletion polymorphism of
the ACE gene identifies patients at increased risk of renal injury
or accelerated loss of renal function [40, 41].
Gabow et al have also identified a number of factors, other than
the PKD 1 locus, which may account for the variable decline of
renal function in ADPKD [16]. These include the presence of
systemic hypertension, male sex, the number and size of renal
cysts, the number of pregnancies in females and recurrent urinary
tract infections. Other studies have suggested the phenotype of
affected individuals is influenced by the genetic contribution from
the parent who does not have ADPKD, although the exact nature
of this influence is not known [42]. In our study we found no
difference between males and females with regards to age of onset
of ESRF. These findings are in contrast to some studies [2, 12],
hut are in agreement with other studies in ADPKD [3, 43].
Although our study has identified an association of the ACE
gene polymorphism with age of onset of ESRF in PKD1, several
potential biases need to be considered that may affect the overall
strength of the observation. Due to the long natural history of
ADPKD by necessity this is a retrospective analysis. As with all
retrospective data, information maybe incomplete. Data on age at
onset and severity of hypertension were not considered suitable
for analysis. In addition, it was not possible to establish whether
renal function, the urinary tract infection rate, or the number and
size of renal cysts varied between groups.
Despite the limitations of the present study, our work and those
of others have identified several genetic and environmental
factors that accelerate rather than delay the onset of renal failure.
Of interest, our findings are similar to previously published results
demonstrating a reduction in the influence of the DD genotype in
the subgroup of patients who reach ESRF after the age of 50 [23,
40, 44]. It has been suggested that the DD polymorphism is
underrepresented in these older patients due to a high cardiovas-
cular mortality associated with the DD polymorphism [451. Be-
cause of the relatively small size of our study, and the presence of
other likely confounding variables such as smoking history and
serum cholesterol, it was not possible to determine whether the
DD polymorphism contributes to accelerated cardiovascular dis-
ease in our group of patients.
The mechanism by which the ACE deletion polymorphism may
contribute to accelerated loss of renal function is unclear. Rigat
has demonstrated that this intragenic polymorphic site accounts
for approximately 50% of the inter-individual variation in serum
ACE levels [11]. Patients homozygous for the deletion polymor-
phism have significantly higher serum and tissue levels of ACE
compared to patients homozygous for the insertion allele [31, 32].
Within the kidney, ACE activity is the rate-limiting step of the
renin-angiotensin enzyme cascade [331. It is proposed that in-
creased levels of ACE result in increased production of the
biologically active ligand, angiotensin II. To support this hypoth-
esis, Ueda et al reported that patients with the DD genotype had
a greater rise in blood pressure in response to an infusion of
angiotensin I than patients with the II genotype [46].
In ADPKD, recent studies have demonstrated enhanced circu-
lating and renal renin activity [14, iS, 18, 47]. Angiotensin II may
act as a growth factor on renal tubular cells leading to increased
cyst size and number, thereby causing impairment of renal
function. Alternatively, increased angiotensin II levels may be
responsible for the early development of severe hypertension.
Only longitudinal studies will be able to determine potential
mechanisms by which the ACE gene deletion polymorphism
exerts its effect on age at onset of ESRF.
Recent studies suggest that the deletion polymorphism may
also have therapeutic implications. In patients with IgA nephrop-
athy, angiotensin converting inhibitors (ACEI) reduce proteinuria
to a greater extent in patients with DD polymorphism compared
to those with II and ID genotypes [24, 48]. However, an effect of
ACEI on the rate of change of GFR in patients with DD
polymorphism has not been established [24, 27]. In patients with
type 1 diabetic nephropathy, therapy with ACEI at standard doses
does not prevent an accelerated deterioration in renal function in
patients with DD genotype [27]. For these patients, it has been
suggested that ACE! should be initiated earlier in the natural
history of renal injury and at higher doses. It has been hypothe-
sized that the variability of ACE! action may be due to differing
effects on DD, ID and II ACE gene polymorphism. In our study
the association of the ACE gene polymorphism with early onset of
ESRF may reflect accelerated deterioration of renal function or
may reflect earlier onset of renal dysfunction. It remains to be
tested if there is a beneficial effect ofACEI in delaying the onset
of ESRF in patients coexpressing the PKDJ ADPKD with ACE
gene DD polymorphism.
A further possibility is that the DD polymorphism has no
functional significance, but is linked to other genes on chromo-
some 17 that result in accelerated progression of renal disease. In
support of this hypothesis, recent studies have suggested the
presence of two quantitative trait loci that account for some of the
inter-individual variation in circulating and tissue angiotensin
converting enzyme levels [49, 501. It may be that the ACE gene
polymorphism acts only as a prognostic marker of accelerated
renal injury. Only a clearer understanding of the mechanisms
involved in the control of circulating and tissue ACE levels, as well
as an appreciation of the functional significance ofACE insertion!
deletion polymorphism will clarify the role of the deletion poly-
morphism in renal injury.
We believe that these data strongly support the concept of a
clinically important genetically determined influence on PKDJ
expression. Furthermore, the data are consistent with those from
several other studies suggesting that homozygosity for the ACE
gene deletion allele identifies a group of patients with both
glomerular and tubular injury with a poor renal prognosis.
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